Skip to content

Pioneering the Future of Cancer Treatment: Highlights from the Third Annual NCI Chemical Biology Consortium Symposium

News Banner entitled Highlights from the 3rd Annual NCI CBC Symposium

The National Cancer Institute (NCI) and Sanford Burnham Prebys (SBP) successfully completed the third annual NCI Chemical Biology Consortium (CBC) Symposium on January 31, 2024, at the Sanford Consortium for Regenerative Medicine in La Jolla, California. This year’s symposium, a testament to the spirit of innovation and collaboration, focused on the advancements in the discovery and development of novel cancer therapeutics, and IRBM was proud to participate.

The CBC, the discovery engine of the NCI’s Experimental Therapeutics (NExT) Program, was established to accelerate the development of new oncology medicines. Administered through the Frederick National Laboratory for Cancer Research, the CBC operates as a collaborative network of leading institutes with expertise spanning from target identification to proof-of-concept clinical trials. In 2023, IRBM was selected to join this prestigious consortium, and the company brings a strong track record and global expertise to the CBC network, further enriching the consortium’s collaborative efforts.

This year’s symposium brought together an impressive array of scientists and researchers from the CBC membership, including IRBM, and the vibrant San Diego cancer research community. The event aimed to share groundbreaking research and foster a collaborative environment where academia and biotechnology companies could unite to expedite the development of new cancer treatments.

IRBM’s Chief Scientific Officer, Carlo Toniatti, and Head of Oncology, Alessandro Carugo, were among the distinguished participants. They shared insights into the latest trends in oncology research, emphasizing the systematic approach to identifying molecular glues, the potential for cross-functional benefits of anti-cancer therapies in treating rare diseases, and the integration of machine learning to unveil new therapeutic targets.

Carlo Toniatti and Alessandro Carugo at the Catch the Wave CBC Symposium next to the event flyer

The symposium showcased current projects across a wide spectrum of cancer research, from early-stage discovery efforts to the latest in therapeutic development. A poster session provided a deeper dive into specific studies, allowing attendees to engage directly with researchers and explore the intricacies of their work.

Moreover, the event dedicated ample time for networking, encouraging participants to build connections and discuss potential collaborations. This interaction is crucial for fostering new partnerships that can push forward the boundaries of cancer therapy.

The involvement of the San Diego cancer research scientific community highlighted the region’s role as a hub of innovation and discovery in the fight against cancer. The enthusiasm and participation from this community not only contributed to the symposium’s success but also underscored the collective commitment to overcoming one of humanity’s most challenging diseases.

Reflecting on the achievements of this year’s symposium, we are reminded of the power of collaboration and the increasing need for new technologies, such as artificial intelligence, in advancing the field of oncology. The innovative research presented and the connections formed throughout the event promise to accelerate the development of new cancer therapies, bringing hope to patients and families affected by this disease.

We extend our heartfelt thanks to all the participants, speakers, and organizers of the third annual NCI CBC Symposium for their contributions to this pivotal event. Together, we are paving the way for a future where cancer can be effectively treated and ultimately cured.


Back To Top